MOU to develop early pancreatic cancer diagnosis platform
Released
Released
Announcement PDF
Company Announcement
ASX: IBX
11 August 2023
Prestige Biopharma and Imagion Biosystems Sign an MOU, Developing
Early Pancreatic Cancer Diagnosis Platform
Singapore, and San Diego, California - PresƟge Biopharma, a biopharmaceuƟcal company specializing
in innovaƟve anƟbody therapies, with a strong dedicaƟon to tackling pancreaƟc cancer, and Imagion
Biosystems, the pioneer in molecular MagneƟc Resonance Imaging (MRI) dedicated to changing the
way we see cancer, have announced the establishment of a strategic partnership through signing a
Memorandum of Understanding (MOU). Together, the companies will jointly pursue the
development of the world’s first non-invasive early detecƟon diagnosis and staging plaƞorm for
pancreaƟc cancer. This potenƟally groundbreaking collaboraƟon between the molecular MRI
innovator listed on the Australian Stock Exchange (ASX: IBX), and a biopharmaceuƟcal company listed
on the Korean Stock Exchange marks a significant leap forward in the fight against one of the most
lethal forms of cancer.
OŌen referred to as the “silent killer,” healthcare systems globally lack a reliable method for early
detecƟon or diagnosis of pancreaƟc cancer, with approximately 80% of paƟents being diagnosed at
stage 4 with terminal disease. Recognizing the need for an early detecƟon soluƟon, PresƟge
Biopharma aims to leverage its unique target protein PAUF as a biomarker, which is overexpressed in
more than 80% of pancreaƟc cancer paƟents, along with Imagion Biosystems’ next-generaƟon
molecular MRI plaƞorm technology to explore possibiliƟes for early pancreaƟc cancer diagnosis.
Establishing earlier pancreaƟc cancer diagnosis paves the way for the subsequent focus on treatment
strategies. Combining MagSense® molecular MRI and PresƟge Biopharma’s PAUF-based anƟbody
drug, PBP1510 aims to accelerate accurate diagnosis and therapeuƟc intervenƟon.
The MOU covers preclinical feasibility research that should be completed in a maƩer of months.
Should the research produce favorable results, both companies may then agree to expand the
collaboraƟon to further advance the technologies. Both companies will bear their own costs during
the period of the MOU with expenses during this phase well within the scope of normal preclinical
feasibility R&D iniƟaƟves.
“We are very pleased to form a strategic partnership with Imagion Biosystems,” stated Lisa Park, CEO
of PresƟge Biopharma. “PresƟge Biopharma Group has made significant progress in building the
pancreaƟc cancer therapeuƟcs system, encompassing diagnosis, treatment, and even prevenƟon. It is
an honor for us to take a step closer to achieving our goal in pancreaƟc cancer diagnosis through the
partnership with Imagion Biosystems.”
“This is an important opportunity to deploy our MagSense® molecular MRI plaƞorm technology for
improved detecƟon and diagnosis of solid tumors and metastaƟc disease.”, said Dr. Isaac J. Bright,
CEO of Imagion Biosystems. “PresƟge Biopharma is an innovaƟve collaborator with whom we intend
to accelerate access to, and improve management opƟons for pancreaƟc cancer paƟents and their
healthcare providers globally.”
ENDS
About PresƟge Biopharma:
Established in 2015, PresƟge Biopharma is a Singapore-based biopharmaceuƟcal company with a
diversified porƞolio, including two novel anƟbody drugs and biosimilars of three blockbuster drugs.
PBP1510 (INN: Ulenistamab) anƟ-PAUF mAb for pancreaƟc cancer, has been designated as an orphan
drug by the FDA, EMA, and MFDS in 2021. It is currently undergoing Phase 1/2a clinical trials in the
United States and Europe and has recently been granted FDA Fast Track designaƟon. PresƟge
Biopharma has also parƟcipated in the Biden administraƟon’s Cancer Moonshot Project, to be part of
the team dedicated to boost innovaƟon in the fight against cancer.
About Imagion Biosystems
Established in 2017 and headquartered in the San Diego, California, US, Imagion Biosystems is an ASXlisted company dedicated to developing innovaƟve medical imaging technologies for various cancer
types. Imagion Biosystems is advancing clinical development of its MagSense® plaƞorm technology to
revoluƟonize cancer diagnosis, introducing molecular imaging to MRI. The Company’s lead program
has demonstrated its innovaƟve technology embodied in MagSense® HER2 Imaging Agent (MSH2IA)
is safe and well-tolerated in paƟents with diagnosed HER2+ breast cancer. Imagion Biosystems’
MagSense® pipeline includes prostate cancer, ovarian cancer, and brain cancer programs advancing
towards clinical development.
For more informaƟon, visit hƩps://imagionbiosystems.com/investor-hub/
Imagion Biosystems InteracƟve Investor Hub
Engage with us directly by asking quesƟons, watching video summaries, and seeing what other
shareholders have to say about this and past announcements at our Investor Hub:
hƩps://investorhub.imagionbiosystems.com/
AuthorisaƟon & AddiƟonal informaƟon
This announcement was authorised by the Disclosure CommiƩee of Imagion Biosystems Limited
Australian Media & Investor RelaƟons:
Hannah HowleƩ, WE CommunicaƟons
We-AUImagionBiosystems@we-worldwide.com
+61 450 648 064
U.S. Media Contact
Casie Ost
casie.ost@imagionbio.com
+1-619-693-4428
Share your feedback
Discover